Medications

FDA approves first targeted therapy for HER2-low breast cancer

The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...

Oncology & Cancer

Grant to fuel baking soda cancer therapy research

A $2 million grant from the National Institutes of Health will enable University of Arizona biomedical engineering researchers to improve the way doctors measure the effectiveness of drinking baking soda to fight breast cancer.

page 12 from 40